Structural Heart Devices Market Outlook: Rising Prevalence of Valvular Heart Disease to Drive Market Growth to US$ 32.35 Billion by 2033

As per the latest market research by Business Market Insights (BMI), the research report "Structural Heart Devices Market Outlook Size and Forecast (2026–2033)" forecasts how the market is set to surge 120.7% by 2033 as the rising prevalence of valvular heart disease reshapes the structural heart devices ecosystem. The report highlights growing adoption of minimally invasive structural heart procedures, revolutionizing the global landscape of structural heart devices market.

The report forecasts the market to expand from US$ 14.66 billion in 2025 to US$ 32.35 billion by 2033, registering a robust CAGR of 10.4% over the 2026–2033 period.

Growing adoption of minimally invasive structural heart procedures is expanding demand for specialized devices by enabling clinicians to treat complex valve conditions without conventional open-heart surgery. Transcatheter aortic valve implantation (TAVI), transcatheter mitral edge-to-edge repair (TEER), and emerging tricuspid interventions provide catheter-based alternatives that can reduce surgical trauma and support faster patient recovery. The American Heart Association notes that TAVI and TEER can involve shorter hospital stays, reduced recovery times, and less trauma than traditional surgical approaches, making these procedures attractive for appropriately selected patients. Healthcare providers are therefore increasingly developing dedicated structural heart programs, investing in catheterization laboratories, advanced imaging capabilities, and multidisciplinary heart teams to support procedural expansion. Clinical guidelines have also established transcatheter interventions for selected patients based on anatomical suitability, surgical risk, symptoms, and expected clinical benefit, strengthening physician confidence in minimally invasive treatment pathways. Recent advances are extending these approaches beyond aortic and mitral valves toward tricuspid disease, creating additional opportunities for device manufacturers to address previously limited treatment options. Hospitals also recognize operational advantages from shorter stays and lower requirements for intensive care associated with TAVI, which can improve capacity utilization and facilitate treatment of additional patients. As physicians gain greater procedural experience and device technologies become more sophisticated, minimally invasive approaches are becoming increasingly integrated into structural heart treatment pathways. This sustained shift toward catheter-based care is stimulating demand for transcatheter valves, repair systems, delivery platforms, and related imaging technologies, supporting continued expansion of the structural heart devices market.

Overview of report findings

Market Growth

The Structural Heart Devices Market is projected to grow from US$ 14.66 billion in 2025 to US$ 32.35 billion by 2033, registering a compound annual growth rate (CAGR) of 10.4% between 2026 and 2033.

The rising prevalence of valvular heart disease and growing adoption of minimally invasive structural heart procedures are key factors propelling market growth. Improving reimbursement for structural heart procedures is transforming the landscape of structural heart devices market.

Rising prevalence of valvular heart disease

The rising prevalence of valvular heart disease is increasing the need for effective diagnostic, repair, and replacement solutions, supporting demand for structural heart devices. Conditions such as aortic stenosis, mitral regurgitation, tricuspid regurgitation, and other valve abnormalities can progressively impair cardiac function and require timely clinical intervention when symptoms worsen or disease severity advances. Improved diagnostic capabilities, including echocardiography and other cardiac imaging technologies, are also enabling healthcare providers to identify structural abnormalities earlier and assess patients more accurately for intervention. This is expanding the addressable patient base for surgical and transcatheter treatment options. Structural heart devices play an important role in managing these conditions through heart valve replacement and repair, annuloplasty, and other catheter-based interventions. The increasing preference for minimally invasive procedures further strengthens demand, as transcatheter approaches can provide treatment alternatives for patients considered unsuitable or high-risk for conventional open-heart surgery. Healthcare providers are also expanding specialized structural heart programs and multidisciplinary heart teams to manage complex valve disorders, which is improving access to advanced procedures. In addition, growing clinical evidence supporting transcatheter valve therapies is encouraging their use across a broader range of patient profiles. Device manufacturers are responding by developing valves and delivery systems designed to improve procedural precision, accommodate complex anatomies, and support better clinical outcomes. As diagnosis rates improve and more patients become eligible for intervention, healthcare systems are expected to continue expanding the use of structural heart technologies. This sustained clinical need for valve repair and replacement procedures is expected to strengthen demand for innovative structural heart devices across major healthcare markets.

Improving reimbursement for structural heart procedures

Improving reimbursement for structural heart procedures is strengthening the economic feasibility of advanced cardiac interventions and encouraging healthcare providers to expand access to minimally invasive treatment options. Favorable coverage policies allow hospitals and physicians to recover the substantial costs associated with specialized devices, imaging systems, catheterization laboratories, trained clinical teams, and post-procedure monitoring. In the United States, Medicare coverage already supports procedures such as transcatheter aortic valve replacement (TAVR) and transcatheter edge-to-edge repair (TEER) under defined clinical conditions, providing an established reimbursement pathway for widely adopted structural interventions. As payers broaden coverage criteria in response to clinical evidence, providers gain greater confidence in adopting newer technologies and expanding dedicated structural heart programs. More predictable payment structures can support hospital investment in advanced infrastructure and multidisciplinary heart teams, enabling facilities to perform a wider range of complex procedures. Reimbursement progress for emerging therapies, including transcatheter approaches targeting mitral and tricuspid valve conditions, can further encourage manufacturers to develop innovative devices that address previously underserved clinical needs. CMS's ongoing evaluation of TAVR coverage demonstrates how evolving evidence and policy assessment can influence future access to these interventions. As reimbursement frameworks become more responsive to clinical outcomes, healthcare institutions can allocate resources toward technologies that demonstrate meaningful patient benefits. This financial support strengthens provider adoption, improves treatment accessibility, stimulates investment in device innovation, and supports sustained demand for structural heart technologies across hospitals and specialized cardiac centers.

Geographic Insights

North America holds the largest share in the structural heart devices market supported by the widespread availability of advanced cardiac care infrastructure and the strong adoption of minimally invasive treatment procedures. The region has a well-established network of specialized cardiac centers and catheterization laboratories capable of performing complex interventions, including transcatheter aortic valve replacement, mitral valve repair, and left atrial appendage closure. High awareness of structural heart conditions, favorable access to advanced diagnostic technologies, and the presence of major medical device manufacturers further support market growth. Continued clinical innovation and the increasing use of catheter-based alternatives to conventional open-heart surgery also strengthen the region's leading position. Europe represents the second-largest regional market, driven by its established healthcare systems, strong clinical expertise, and growing adoption of transcatheter structural heart interventions. Countries across the region have expanded the use of minimally invasive procedures for treating valvular heart diseases and other structural cardiac abnormalities. The presence of experienced cardiology centers, increasing focus on early diagnosis, and ongoing technological advancements in heart valve and closure devices contribute to sustained demand. Asia Pacific is the fastest-growing region in the structural heart devices market. Rising healthcare expenditure, improving access to specialized cardiovascular treatment, and the expansion of hospitals and cardiac care facilities are creating new opportunities for device adoption. Growing awareness of minimally invasive treatment options and increasing investment in advanced medical technologies are also supporting regional growth. In addition, large patient populations and the gradual development of interventional cardiology capabilities across emerging economies are expected to accelerate the adoption of structural heart devices.

Market Segmentation

• By product type, the structural heart devices market is segmented into heart valve devices, occluders and closure devices, left atrial appendage (LAA) closure devices, annuloplasty rings & bands, and delivery systems & accessories. The heart valve devices segment dominated the market in 2025. The high prevalence of valvular heart diseases, increasing adoption of minimally invasive and transcatheter valve replacement and repair procedures, and continued advancements in bioprosthetic and transcatheter valve technologies have supported the segment's leading position.
• On the basis of application, the structural heart devices market is categorized into valvular heart disease, congenital & septal defects, atrial fibrillation & stroke prevention, and others. The valvular heart disease segment dominated the market in 2025. The growing utilization of transcatheter aortic valve replacement and other minimally invasive interventions, coupled with the rising demand for effective treatment options for aortic, mitral, and other valve disorders, has contributed to the segment's dominance.
• Based on age group, the structural heart devices market is categorized into adult and pediatric. The adult segment dominated the market in 2025. A higher incidence of structural and valvular heart conditions among adults, along with greater adoption of transcatheter and surgical interventions for conditions such as aortic stenosis and mitral regurgitation, has driven the demand for structural heart devices within this patient group.
• In terms of end user, the structural heart devices market is categorized into hospitals, cardiac catheterization labs, ambulatory surgical centers (ASCs), and others. The hospitals segment dominated the market in 2025. Their access to specialized cardiologists and cardiac surgeons, advanced imaging and surgical infrastructure, and ability to manage complex structural heart procedures and post-procedure care have supported their position as the leading end-user category.

Competitive Strategy & Development

Key Players: The Structural Heart Devices Market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

1. Boston Scientific Corporation
2. Medtronic Plc
3. Abbott
4. Edwards Lifesciences Corp
5. Meril Life Sciences Pvt Ltd
6. MicroPort Scientific Corp
7. B. Braun SE
8. Artivion Inc
9. Teleflex Inc
10. Venus MedTech HangZhou Inc

Trending Topics: Structural heart devices market growth trends, Transcatheter heart valve technology advancements, TAVR and TMVR procedure adoption, Minimally invasive structural heart interventions, Left atrial appendage closure device demand, Congenital heart defect treatment innovations, AI in structural heart disease diagnosis, Next-generation heart valve replacement devices, Structural heart device clinical trial developments, Robotic-assisted structural heart procedures, Rising demand for catheter-based cardiac treatments, Emerging markets structural heart devices, Structural heart device safety and outcomes, Structural heart devices market forecast

Global Headlines

• " JenaValve Trilogy Transcatheter Heart Valve Receives FDA Approval, in March 2026, JenaValve announced FDA approval of the Trilogy Transcatheter Heart Valve System for treating symptomatic severe aortic regurgitation in eligible patients at high risk for surgical mortality, expanding minimally invasive treatment options for aortic valve disease."

• " TRiCares Receives FDA Approval for TRICURE US IDE Pivotal Trial, in April 2026, TRiCares announced FDA approval for its U.S. Investigational Device Exemption pivotal trial evaluating the Topaz Tricuspid Valve Replacement System, advancing development of a transcatheter replacement option for patients with tricuspid valve disease and supporting the expansion of minimally invasive structural heart therapies."

• “Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves, in June 2026, Edwards Lifesciences announced new clinical data covering its aortic, mitral, and tricuspid structural heart therapies, including the PROGRESS trial evaluating whether earlier transcatheter aortic valve replacement could benefit selected patients with moderate aortic stenosis and additional risk factors. The update highlights continued advancement of Edwards’ transcatheter structural heart technologies and expansion of evidence supporting earlier intervention.”

Conclusion

The structural heart devices market is positioned for sustained growth as cardiovascular care continues to shift toward less invasive treatment approaches. The rising prevalence of valvular heart disease remains a major demand driver, particularly as healthcare systems improve diagnosis and referral of patients requiring intervention. At the same time, growing adoption of minimally invasive structural heart procedures is expanding the use of transcatheter technologies among patients who may face greater risks from conventional surgery. Improving reimbursement for structural heart procedures in key markets is also supporting broader patient access and encouraging healthcare providers to invest in specialized treatment capabilities. Despite these favorable conditions, market expansion faces several challenges. The high cost of structural heart devices can restrict adoption, particularly in healthcare systems with constrained budgets or limited reimbursement coverage. Procedural and device-related complications may also influence physician and patient acceptance, while product recalls and device discontinuations can affect clinical confidence and increase scrutiny of device safety and performance. Significant opportunities are emerging as manufacturers expand transcatheter mitral and tricuspid therapies beyond established aortic interventions. Earlier treatment of valve disease could further broaden the eligible patient population as clinical practice increasingly emphasizes timely intervention before disease progression causes substantial cardiac damage. The growing geriatric population is expected to reinforce long-term demand for structural heart interventions as age-related cardiovascular conditions become more prevalent. Technological development will remain central to competitive differentiation. The increasing adoption of transcatheter edge-to-edge repair (TEER) is strengthening minimally invasive options for patients with mitral and tricuspid valve disorders. Meanwhile, the development of smaller, more flexible, and easier-to-deliver devices is expected to simplify procedures, improve navigation through challenging anatomy, and expand treatment options. Together, these developments are expected to shape innovation, clinical adoption, and competitive dynamics across the structural heart devices market.